[go: up one dir, main page]

SI9010243B - Substituirani 1,3-oksatiolani z antivirusnimi lastnostmi - Google Patents

Substituirani 1,3-oksatiolani z antivirusnimi lastnostmi Download PDF

Info

Publication number
SI9010243B
SI9010243B SI9010243A SI9010243A SI9010243B SI 9010243 B SI9010243 B SI 9010243B SI 9010243 A SI9010243 A SI 9010243A SI 9010243 A SI9010243 A SI 9010243A SI 9010243 B SI9010243 B SI 9010243B
Authority
SI
Slovenia
Prior art keywords
oxathiolane
compound
formula
group
hydroxymethyl
Prior art date
Application number
SI9010243A
Other languages
English (en)
Other versions
SI9010243A (en
Inventor
Bernard Belleau
Pierette Belleau
Nghe Nguyen-Ba
Original Assignee
Biochem Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25678044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI9010243(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biochem Pharma Inc. filed Critical Biochem Pharma Inc.
Priority claimed from CA002152269A external-priority patent/CA2152269C/en
Publication of SI9010243A publication Critical patent/SI9010243A/sl
Publication of SI9010243B publication Critical patent/SI9010243B/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)

Claims (12)

  1. -λ" PATENTNI ZAHTEVKI 1. Postopek za pridobivanje spojine s formulo (I)
    (I) kjer je Rj vodik; I^ je purinska ali pirimidinska baza ali njen analog ali derivat; Z je S, S=0 ali S02; in njenih farmacevtsko sprejemljivih derivatov, označen s tem, da obsega: (a) reakcijo spojine s formulo (VIII)
    (VIII) v kateri je R; vodik ali zaščitna skupina za hidroksilno skupino in je L zamenljiv atom ali skupina z bazno R^H skupino; (b) bazno interkonverzijo spojine s formulo (I) v drugo spojino s formulo (I); (c) reakcijo spojine s formulo (IX)
  2. 2. Postopek po zahtevku 1, označen s tem, da spojino s formulo (I) dobimo v obliki tis izomera.
    2 (IX) *
    s spojino s formulo (X) PO
    CHO v kateri je P zaščitna skupina; ali (X) -Z' (d) konverzijo spojine s formulo (XII)
    (XII) v spojino s formulo (I), in če je potrebno ali želeno, izpostavitev spojine, dobljene v katerekoli stopnji od (a) do (d), eni ali dvem nadaljnjim reakcijam, ki obsegata: (i) odstranjevanje katerekoli zaščitne skupine; (ii) pretvorbo spojine s formulo (I) ali njene soli v njeno farmacevtsko sprejemljivo sol.
  3. 3. Postopek po zahtevku 1 ali 2, označen s tem, da Z predstavlja S.
  4. 4. Postopek po kateremkoli od zahtevkov 1 do 3, označen s tem, da je R2:
    'N -'b-
    o
    je R3 izbran iz skupine, ki jo sestavljajo vodik, trifluorometil ali nasičena ali nenasičena C16alkilna skupina; ·* R4 in R. sta neodvisno izbrana iz skupine, ki jo sestavljajo vodik, hidroksimetil. tri-tluorometil, substituiran ali nesubstituiran, nasičen ali nenasičen Ct 6alkil, brom. klor, fluor ali jod; R6 je izbran iz skupine, ki jo sestavljajo vodik, ciano, karboksi, etoksikarbonil. kar* bamoil ali tiokarbamoil; in sta X in Y sta neodvisno izbrana iz skupine, ki jo sestavljajo vodik, brom. klor. tluor, jod. amino ali hidroksilna skupina.
  5. 5. Postopek po kateremkoli od zahtevkov 1 do 3, označen s tem, daje R2: -Ni
    kjer je R3 izbran iz skupine, ki jo sestavljajo vodik, trifluorometil ali nasičena ali nenasičena C16alkilna skupina in je R4 izbran iz skupine, ki jo sestavljajo vodik, hidroksimetil, trifluorometil, substituirana ali nesubstituirana, nasičena ali nenasičena C3 6alkilna skupina, brom, klor, fluor ali jod.
  6. 6. Postopek po kateremkoli od zahtevkov 1 do 5, označen s tem, da spojino s formulo (I) izberemo izmed: Cis-2-hidroksimetil-5-(citozin-Γ-il)-1.3-oksatiolana, trans-2-hidroksimetil-5 -f citozin-l’-il)-l,3-oksatiolana in njunih zmesi; Cis-2-benzoilksimetil-5-(citozin-l’-il)-l,3-oksatiolana, trans-2-benzoiloksimetil-5-(citozin-l’-il)-l,3-oksatioIana in njunih zmesi; Cis-2-hidroksimetil-5-(N4’-acetil-citozin-l’-il)-l,3-oksatiolana, trans-2-hidroksimetil-5-(N4’-acetil-citozin-l’-il)-l,3-oksatiolana in njunih zmesi; Cis-2-benzoiloksimetil-5-(N4’-acetil-citozin-l’-il)-l,3-oksatiolana, trans-2-benzoiloksimetil-5-(N4’-acetil-citozin-l’-il)-l,3-oksatiolana in njunih zmesi; in Qs-2-hidroksimetil-5-(citozin-l’-il-3-okso-l,3-oksatiolana); Cis-2-hidroksimetil-5-(N-dimetilamino-metilen citozin-l’-il)-l,3-oksatiolana; Bis-cis-2-sukciniloksimetil-5-(citozin-r-iD-l,3-oksatiolana; Cis-2-benzoiloksimetil-5-(6’-kloropurin-N-9’-il)-l,3-oksatiolana; trans-2-benzoiloksimetil-5-(6’-kloropurin-N-9’-il)-l,3-oksatiolana in njunih zmesi; Cis-2-hidroksimetil-5-(6’-hidroksipurin-N-9’-il)-l,3-oksatiolana; Cis-2-benzoiloksimetil-5-(uracil-N-r*il)-l,3-oksatiolana, trans-2-benzoiloksimetil-5- -5 " (uracil-N-l’-il)-l,3-oksatiolana in njunih zmesi; Cis-2-hidroksimetil-5-(uraciI-N-r-iQ-l,3-oksatiolana; Cis-2-benzoiloksimetil-5-(timin-N-r-il)-l,3-oksatiolana, trans-2-benzoiloksimetil-5-(timin-N-l’-il)-l,3-oksatiolana in njunih zmesi; Qs-2-hidroksimetil-5-(timin-N-l’-il)-l,3-oksatiolana; in njihovih farmacevtsko sprejemljivih derivatov v obliki racemnih zmesi ali posameznih enantiomerov.
  7. 7. Postopek po kateremkoli od zahtevkov 1 do 5, označen s tem, da je spojina s formulo (I) Cis-2-hidroksimetil-5-(citozin-r-il)-l,3-oksatiolan in njegovi farmacevtsko sprejemljivi derivati.
  8. 8. Postopek po kateremkoli od zahtevkov 1 do 7, označen s tem, da spojino s formulo (I) dobimo v obliki racemne zmesi.
  9. 9. Postopek po kateremkoli od zahtevkov 1 do 7, označen s tem, da spojino s formulo (I) dobimo v obliki posameznega enantiomera.
  10. 10. Postopek po kateremkoli od zahtevkov 1 do 9, označen s tem, da v stopnji (a) skupino L izberemo iz skupine, ki jo sestavljajo alkoksikarbonil, jod, brom, klor ali -OR, kjer je R substituirana ali nesubstituirana, nasičena ali nenasičena alkilna skupina ali je R substituirana ali nesubstituirana alifatska ali aromatska acilna skupina.
  11. 11. Postopek po kateremkoli od zahtevkov 1 do 10, označen s tem, da v stopnji (a) spojina s formulo (VIII) reagira s sililirano purinsko ali pirimidinsko bazo v ustreznem topilu v prisotnosti Lewisove kisline ali trimetilsililtriflata.
  12. 12. Postopek za pripravo farmacevtskega pripravka, označen s tem, da obsega mešanje spojine s formulo (I), kot je definirana v zahtevku 1, ali njenega farmacevtsko sprejemljivega derivata s farmacevtsko sprejemljivim nosilcem. Za BioChem Pharma Inc.:
SI9010243A 1989-02-08 1990-02-08 Substituirani 1,3-oksatiolani z antivirusnimi lastnostmi SI9010243B (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/308,101 US5047407A (en) 1989-02-08 1989-02-08 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
YU24390A YU48840B (sh) 1989-02-08 1990-02-08 Postupak za dobijanje substituisanih 1,3-oksatiolana sa antivirusnim osobinama
CA002152269A CA2152269C (en) 1989-02-08 1992-12-21 Process for preparing substituted 1,3-oxathiolanes with antiviral properties

Publications (2)

Publication Number Publication Date
SI9010243A SI9010243A (en) 1996-10-31
SI9010243B true SI9010243B (sl) 1998-08-31

Family

ID=25678044

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9010243A SI9010243B (sl) 1989-02-08 1990-02-08 Substituirani 1,3-oksatiolani z antivirusnimi lastnostmi

Country Status (35)

Country Link
US (1) US5047407A (sl)
EP (2) EP0382526B1 (sl)
JP (4) JP2644357B2 (sl)
KR (1) KR960007531B1 (sl)
CN (1) CN1033640C (sl)
AP (1) AP136A (sl)
AT (2) ATE254125T1 (sl)
AU (1) AU630913B2 (sl)
CA (1) CA2009637C (sl)
CY (1) CY2036A (sl)
CZ (1) CZ282720B6 (sl)
DE (3) DE69026971T2 (sl)
DK (2) DK0382526T3 (sl)
ES (2) ES2206476T3 (sl)
FI (1) FI98065C (sl)
GR (1) GR3019919T3 (sl)
HK (2) HK51997A (sl)
HR (1) HRP940040B1 (sl)
HU (2) HU208134B (sl)
IE (1) IE72184B1 (sl)
IL (1) IL93318A (sl)
LU (1) LU88809I2 (sl)
MX (1) MX19437A (sl)
NL (1) NL960025I2 (sl)
NO (2) NO179518C (sl)
NZ (1) NZ232421A (sl)
OA (1) OA09193A (sl)
PL (1) PL164785B1 (sl)
PT (1) PT93094B (sl)
RU (1) RU2092485C1 (sl)
SG (2) SG48737A1 (sl)
SI (1) SI9010243B (sl)
SK (1) SK279175B6 (sl)
YU (1) YU48840B (sl)
ZA (1) ZA90943B (sl)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684164A (en) * 1988-04-11 1997-11-04 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US6350753B1 (en) 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US6903224B2 (en) * 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
ATE237613T1 (de) * 1989-02-08 2003-05-15 Iaf Biochem Int Verfahren für die herstellung von antiviralen substituierten 1, 3-oxathiolanen
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
US6642245B1 (en) * 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5728575A (en) * 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5700937A (en) * 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5587480A (en) * 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
AU8864191A (en) * 1990-11-13 1992-06-11 Biochem Pharma Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US6369066B1 (en) 1990-11-13 2002-04-09 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes with antiviral properties
US6228860B1 (en) 1990-11-13 2001-05-08 Biochem Pharma Inc. Substituted 1,3-oxathiolanes with antiviral properties
AU9125991A (en) * 1990-12-05 1992-07-08 University Of Georgia Research Foundation, Inc., The Enantiomerically pure beta -l-(-)-1,3-oxathiolane nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
NZ250842A (en) * 1991-02-22 1996-03-26 Univ Emory Resolution of a racemic mixture of nucleoside enantiomers such as 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (ftc)
US6812233B1 (en) * 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
IL101144A (en) * 1991-03-06 1996-09-12 Wellcome Found Pharmaceutical compositions containing 1-(2-hydroxymethyl)-1,3-oxathiolan-5-fluorocytosine and derivatives thereof for the treatment of hepatitis b virus infections
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9109506D0 (en) * 1991-05-02 1991-06-26 Wellcome Found Therapeutic nucleosides
ES2083668T5 (es) * 1991-05-16 2001-06-16 Glaxo Group Ltd Combinaciones antiviricas que contienen analogos de nucleosido.
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
DK0530407T3 (da) * 1991-09-04 1996-07-29 Stichting Rega V Z W Substituerede nukleosidderivater, fremgangsmåder til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
US20050192299A1 (en) * 1992-04-16 2005-09-01 Yung-Chi Cheng Method of treating or preventing hepatitis B virus
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
ATE184787T1 (de) * 1992-05-13 1999-10-15 Wellcome Found Therapeutische kombinationen
US6005107A (en) 1992-12-23 1999-12-21 Biochem Pharma, Inc. Antiviral compounds
US6444656B1 (en) 1992-12-23 2002-09-03 Biochem Pharma, Inc. Antiviral phosphonate nucleotides
GB9226879D0 (en) * 1992-12-23 1993-02-17 Iaf Biochem Int Anti-viral compounds
GB9311709D0 (en) * 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
AU7954694A (en) 1993-09-10 1995-03-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis b virus activity
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
FR2720397B1 (fr) * 1994-05-24 1996-08-23 Laphal Laboratoires Sa Nouveaux oxathiolanes, leur procédé de préparation et les compositions pharmaceutiques qui en renferment.
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
AU5527196A (en) * 1995-04-04 1996-10-23 Brigham And Women's Hospital Inhibiting retroviral replication
WO1996040164A1 (en) * 1995-06-07 1996-12-19 Emory University Nucleosides with anti-hepatitis b virus activity
GB9605293D0 (en) * 1996-03-13 1996-05-15 Glaxo Group Ltd Medicaments
FR2746396B1 (fr) * 1996-03-20 1998-06-05 Inst Nat Sante Rech Med 1,3-thiazolidin-4-ones et 1,3-thiazolidines substituees, procede d'obtention de ces composes et leurs utilisations comme medicaments
AP9801419A0 (en) 1996-06-25 1998-12-31 Glaxo Group Ltd Combination comprising VX478, zidovudine, FTC and or 3
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
US5792773A (en) * 1996-11-15 1998-08-11 Yale University L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection
US20040044016A1 (en) * 1997-01-31 2004-03-04 Mitsubishi Chemical Corporation Antiviral agents
EA001920B1 (ru) 1997-03-19 2001-10-22 Эмори Юниверсити Синтез 1,3-оксаселеноланнуклеозидов, их активность против вируса иммунодефицита человека и против вируса гепатита-b
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
IT1290447B1 (it) * 1997-03-28 1998-12-03 Zambon Spa Derivati 1,3-ossatiolanici ad attivita' antivirale
JP2001518899A (ja) 1997-04-07 2001-10-16 トライアングル ファーマシューティカルズ，インコーポレイティド 他の抗ウイルス剤との組合せにおけるｍｋｃ−４４２の使用
DK1058686T3 (da) 1998-02-25 2007-03-05 Univ Emory 2'-fluornukleosider
EP1754710A3 (en) 1998-02-25 2007-12-19 Emory University 2'-Fluoroncucleosides
DE69921829T2 (de) 1998-08-12 2005-10-27 Gilead Sciences, Inc., Foster City Verfahren zur herstellung von 1,3-oxathiolannukleoside
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
US6528515B1 (en) 1998-11-02 2003-03-04 Triangle Pharmaceuticals, Inc. Combination therapy to treat hepatitis B virus
DE69929460D1 (de) 1998-11-05 2006-04-06 Centre Nat Rech Scient Nukleoside mit anti-hepatitis b virus wirkung
DE69912842T2 (de) * 1998-12-23 2004-05-13 Shire Biochem Inc., Laval Antivirale nukleosidanaloga
NZ529882A (en) * 1999-03-29 2005-05-27 Shire Biochem Inc Methods of treating leukemia
US6752929B1 (en) * 1999-05-26 2004-06-22 Johnson Matthey Pharmaceutical Materials, Inc. Methods of separating FTC isomers and derivatives thereof
EP1180104B1 (en) * 1999-05-26 2003-03-26 Johnson Matthey Pharmaceutical Materials Inc Methods of separating ftc isomers and derivatives thereof
US6653318B1 (en) 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
US6432966B2 (en) * 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
EP1600451A3 (en) 1999-11-12 2008-09-10 Pharmasset, Inc. Synthesis of 2'-deoxy-l-nucleosides
IL149592A0 (en) * 1999-11-12 2002-11-10 Pharmasset Ltd Synthesis of 2'-deoxy-l-nucleosides
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
GB0016845D0 (en) * 2000-07-07 2000-08-30 Leuven K U Res & Dev Pharmaceutical composition for treatment of HIV infection
WO2002051852A1 (fr) * 2000-12-27 2002-07-04 Mitsui Chemicals, Inc. Procede de production d'un derive de saccharide non naturel
ES2253544T3 (es) * 2001-03-01 2006-06-01 Gilead Sciences, Inc. Formas poliformicas y otras cristalinas de cis-ftc.
CA2351049C (en) 2001-06-18 2007-03-13 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
JP2003039582A (ja) * 2001-07-19 2003-02-13 Three M Innovative Properties Co 湿潤防滑性シート及び湿潤防滑構造体
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US6855346B2 (en) * 2001-10-05 2005-02-15 Tzu-Sheng Wu Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same
ES2258668T3 (es) * 2001-10-26 2006-09-01 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hidroxipirimidina carboxamidas n-sustituidas inhibidoras de hiv integrasa.
US20030162992A1 (en) * 2001-12-14 2003-08-28 Watanabe Kyoichi A. Preparation of intermediates useful in the synthesis of antiviral nucleosides
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
BR0313302A (pt) 2002-08-06 2005-06-28 Pharmasset Inc Processos para a preparação de nucleosìdeos de 1,3-dioxolano
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238722A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
JP2006508134A (ja) * 2002-11-08 2006-03-09 グラクソ　グループ　リミテッド 医薬組成物
MXPA05003637A (es) * 2002-12-09 2005-08-16 Univ Georgia Res Found Dioxolan timina y combinaciones para utilizarse contra cepas de vih resistentes.
US20060246130A1 (en) 2003-01-14 2006-11-02 Dahl Terrence C Compositions and methods for combination antiviral therapy
US8044060B2 (en) 2003-05-09 2011-10-25 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE10320785A1 (de) * 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine
DE102004001873A1 (de) * 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
EP1778251B1 (en) 2004-07-27 2011-04-13 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
JP2006214695A (ja) * 2005-02-07 2006-08-17 Sanken Setsubi Kogyo Co Ltd 空調システム
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
WO2007013047A2 (en) * 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited Water-dispersible anti-retroviral pharmaceutical compositions
ES2352216T3 (es) * 2005-08-31 2011-02-16 Cipla Limited Combinaciones farmacéuticas que contienen lamivudina, estavudina y nevirapina.
CN1328240C (zh) * 2005-08-31 2007-07-25 四川大学 苯甲酰氧基乙醛的制备方法
CN101310021A (zh) 2005-09-26 2008-11-19 法莫赛特股份有限公司 作为抗病毒剂的修饰的4’-核苷
AU2006325404B2 (en) * 2005-12-14 2012-03-01 Cipla Limited Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
US8895531B2 (en) * 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
AU2007237818B2 (en) * 2006-04-18 2012-09-27 Lupin Limited A novel crystalline form of lamivudine
EP2086955A2 (en) * 2006-10-30 2009-08-12 Lupin Ltd. An improved process for the manufacture of cis(-)-lamivudine
KR100840495B1 (ko) 2007-04-13 2008-06-23 한미약품 주식회사 라미부딘을 입체선택적으로 제조하는 방법
PT2514750E (pt) 2007-06-18 2014-01-23 Sunshine Lake Pharma Co Ltd Tiazolil dihidropirimidinas substituídas com bromo-fenilo
US20100190982A1 (en) * 2007-09-17 2010-07-29 Janardhana Rao Vascuri Process for the preparation of lamivudine form i
AU2008331166B2 (en) * 2007-11-29 2013-10-10 Ranbaxy Laboratories Limited Process for the preparation of substituted 1,3-oxathiolanes
AU2008331167A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Process and intermediates for the preparation of substituted 1, 3-oxathiolanes, especially lamivudine
WO2009068617A1 (en) * 2007-11-30 2009-06-04 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-d) pyrimidin-4-one derivatives and their use as pde9a modulators for the teatment of cns disorders
UA105362C2 (en) * 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
TW201010692A (en) 2008-06-19 2010-03-16 Public Univ Corp Nagoya City Univ Pharmaceutical composition for treatment or prevention of hbv infection
PE20110383A1 (es) 2008-09-08 2011-07-15 Boehringer Ingelheim Int Pirazolopirimidinonas como inhibidores de la fosfodiesterasa 9a (pde9a)
TWI432436B (zh) 2008-12-09 2014-04-01 Gilead Sciences Inc 類鐸受體的調節劑
WO2010082128A1 (en) 2009-01-19 2010-07-22 Aurobindo Pharma Limited Process for the preparation of cis-nucleoside derivative
GEP20146098B (en) 2009-03-31 2014-05-27 Boehringer Ingelheim Int 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their usage as pde9a modulators
KR101474570B1 (ko) 2009-04-13 2014-12-19 주식회사 대희화학 라미부딘의 신규한 중간체 및 이의 제조방법
AR077859A1 (es) * 2009-08-12 2011-09-28 Boehringer Ingelheim Int Compuestos para el tratamiento de trastornos del snc
DK2488516T3 (en) 2009-10-14 2015-05-26 Mylan Lab Ltd Method of producing lamivudine and novel salts in the preparation thereof
DK3127542T3 (en) 2010-01-27 2018-11-12 Viiv Healthcare Co ANTIVIRAL THERAPY
US20120295930A1 (en) 2010-02-03 2012-11-22 Shankar Rama Novel process for the preparation of cis-nucleoside derivative
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
CN102234269B (zh) * 2010-04-29 2015-09-16 重庆医药工业研究院有限责任公司 拉米夫定的工业化制备方法
WO2011141805A2 (en) 2010-05-14 2011-11-17 Lupin Limited An improved process for the manufacture of lamivudine
CN104203275A (zh) 2010-06-09 2014-12-10 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
CN105541849B (zh) 2010-08-12 2018-03-23 勃林格殷格翰国际有限公司 6‑环烷基‑1,5‑二氢‑吡唑并[3,4‑d]嘧啶‑4‑酮衍生物及其作为PDE9A抑制剂的用途
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
US20130296562A1 (en) 2011-08-05 2013-11-07 Lupin Limited Stereoselective process for preparation of 1,3-oxathiolane nucleosides
WO2013168066A1 (en) 2012-05-05 2013-11-14 Lupin Limited An improved process for the manufacture of lamivudine form i.
CN103694231A (zh) * 2013-11-28 2014-04-02 安徽一帆香料有限公司 一种拉米夫定中间体hdms的合成制备方法
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
CA2954056C (en) 2014-07-11 2020-04-28 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
WO2016033164A1 (en) 2014-08-26 2016-03-03 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
US20180263985A1 (en) 2015-09-15 2018-09-20 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
HUE056978T2 (hu) 2015-12-02 2022-04-28 Merck Sharp & Dohme Doravirint, tenofovir-dizoproxil-fumarátot és lamivudint tartalmazó gyógyszerészeti kompozíciók
US11498933B2 (en) 2017-03-31 2022-11-15 The John Hopkins University Prodrug compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
JPS5259171A (en) * 1975-11-10 1977-05-16 Asahi Chem Ind Co Ltd Preparation of uracil derivatives
JPS6045196B2 (ja) * 1976-08-09 1985-10-08 株式会社興人 １−（２−テトラヒドロフリル）ウラシル類の製造方法
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
JPS56167685A (en) * 1980-05-28 1981-12-23 Taiho Yakuhin Kogyo Kk 1- 2-tetrahydrothiophene-1,1-dioxide -5-fluorouracil and its preparation
JPS56169689A (en) * 1980-06-02 1981-12-26 Taiho Yakuhin Kogyo Kk 3-substituted-5-fluorouracil derivative and its preparation
JPS5738774A (en) * 1980-08-19 1982-03-03 Chugai Pharmaceut Co Ltd Uracil derivative and its preparation
SU1035023A1 (ru) * 1982-03-23 1983-08-15 Ордена Трудового Красного Знамени Институт Органической И Физической Химии Им.А.Е.Арбузова Способ получени 3-(тииранил-2-метил)-6-метилурацилов
DE3324769A1 (de) * 1983-07-08 1985-01-17 Bayer Ag, 5090 Leverkusen 5-aminomethyl-1,3-oxathiolane
FI87783C (fi) * 1985-05-15 1993-02-25 Wellcome Found Foerfarande foer framstaellning av terapeutiskt anvaendbara 2',3'-dideoxinukleosider
CA1294960C (en) * 1986-10-24 1992-01-28 Thomas C. Malone 7-deazaguanines as immunomodulators
DE3712735A1 (de) * 1987-04-15 1988-11-10 Boehringer Mannheim Gmbh Neue pyrazolo(3,4-d)pyrimidine, verfahren zu ihrer herstellung und verwendung als arzneimittel
ES2075040T3 (es) * 1988-02-16 1995-10-01 Lilly Co Eli 2',3'-dideoxi-2',2'-difluoronucleosidos.
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds

Also Published As

Publication number Publication date
HU210537A9 (en) 1995-04-28
NO900619L (no) 1990-08-09
FI98065B (fi) 1996-12-31
YU48840B (sh) 2002-06-19
CS410991A3 (en) 1992-07-15
US5047407A (en) 1991-09-10
JP2644357B2 (ja) 1997-08-25
JP2001226373A (ja) 2001-08-21
DK0382526T3 (da) 1996-08-05
NO900619D0 (no) 1990-02-08
NZ232421A (en) 1993-10-26
OA09193A (en) 1992-06-30
ES2086371T3 (es) 1996-07-01
CN1044817A (zh) 1990-08-22
NO179518B (no) 1996-07-15
NO179518C (no) 2000-09-11
CZ282720B6 (cs) 1997-09-17
ATE254125T1 (de) 2003-11-15
YU24390A (en) 1991-10-31
DE69026971T2 (de) 1996-09-12
HRP940040B1 (en) 2002-04-30
HK1009270A1 (en) 1999-05-28
SK279175B6 (sk) 1998-07-08
CA2009637A1 (en) 1990-08-08
HRP940040A2 (en) 1997-04-30
JPH08119967A (ja) 1996-05-14
IE72184B1 (en) 1997-03-26
HU208134B (en) 1993-08-30
NL960025I1 (nl) 1997-01-06
CY2036A (en) 1998-02-20
DE69034119T2 (de) 2004-08-26
ES2206476T3 (es) 2004-05-16
GR3019919T3 (en) 1996-08-31
IL93318A (en) 1995-07-31
CN1033640C (zh) 1996-12-25
IE960758L (en) 1990-08-08
HUT53362A (en) 1990-10-28
EP0382526B1 (en) 1996-05-15
EP0711771A3 (en) 1996-07-10
SI9010243A (en) 1996-10-31
EP0711771A2 (en) 1996-05-15
FI98065C (fi) 1997-04-10
SG77215A1 (en) 2000-12-19
LU88809I2 (fr) 1997-01-03
HU900708D0 (en) 1990-04-28
JP3105154B2 (ja) 2000-10-30
MX19437A (es) 1993-05-01
KR900012932A (ko) 1990-09-03
IE900452L (en) 1990-08-08
EP0711771B1 (en) 2003-11-12
PT93094B (pt) 1995-12-29
ZA90943B (en) 1990-10-31
DE19675032I2 (de) 2007-11-08
CA2009637C (en) 1997-10-07
AU4920190A (en) 1990-08-16
HK51997A (en) 1997-05-02
DE69026971D1 (de) 1996-06-20
DK0711771T3 (da) 2004-03-22
RU2092485C1 (ru) 1997-10-10
FI900631A0 (fi) 1990-02-08
AP9000163A0 (en) 1990-04-30
JPH037282A (ja) 1991-01-14
AU630913B2 (en) 1992-11-12
ATE138065T1 (de) 1996-06-15
DE69034119D1 (de) 2003-12-18
PL164785B1 (en) 1994-10-31
EP0382526A2 (en) 1990-08-16
KR960007531B1 (ko) 1996-06-05
EP0382526A3 (en) 1992-01-02
AP136A (en) 1991-08-05
SG48737A1 (en) 1998-05-18
NL960025I2 (nl) 1997-03-03
PT93094A (pt) 1990-08-31
NO2001002I1 (no) 2001-02-12
JP2000143662A (ja) 2000-05-26

Similar Documents

Publication Publication Date Title
SI9010243B (sl) Substituirani 1,3-oksatiolani z antivirusnimi lastnostmi
EP0269574A3 (en) Novel adenosine derivatives and pharmaceutical compositions containing them as an active ingredient
WO1994003467B1 (en) Antiretroviral enantiomeric nucleotide analogs
CA2190983A1 (en) New lipid esters of nucleoside monophosphates and their use as immunosuppressive drugs
CA2095613A1 (en) Substituted 1, 3-oxathiolanes and substituted 1, 3-dithiolanes with antiviral properties
HUT54981A (en) Process for producing acryloyl-substituted pyrrole derivatives and pharmaceutical compositions comprising same
DE69908546D1 (de) Imidazopyridinderivate und Verfahren zu ihrer Herstellung
KR940014397A (ko) 비사이클릭 아민 유도체
DE60002755D1 (de) Benzothiadiazinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
AT389108B (de) Neue pyridazinonderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen
DE69007905D1 (de) 1-Oxa-2-oxo-8-azaspiro[4,5]decan-Derivate, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen daraus.
DK0458624T3 (da) Fremgangsmåde til fremstilling af lactamderivater
ATE40997T1 (de) 1,5-benzothiazepin-derivate, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen sowie ihre verwendung.
AU2008203443B2 (en) Stereoselective method for the preparation of nucleoside analogues
ATE23995T1 (de) Pyridin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE41659T1 (de) Benzothiazepinderivate, verfahren zur herstellung und pharmazeutische zusammensetzungen.
KR920016456A (ko) 5-(치환 아미노) -1,2,4-트리아졸로 [1,5-a]피리미딘 유도체
KR927003589A (ko) p-치환된 페닐 4-옥시부탄 아민 유도체, 그것의 제조방법 및 그것을 함유하는 약제조성물
DE69106323D1 (de) Imidazol-Derivate, Verfahren zu deren Herstellung und diese enthaltende Zusammenstellungen.
DE60011787D1 (de) Carbocyclische nukleoside und verfahren zu deren herstellung
DE68917060D1 (de) 2'-Methylidenpyrimidin-Nukleoside, ihre Verwendung und Verfahren zu ihrer Herstellung.
DE3770117D1 (de) Neue 1-/ 3-(2-dialkylaminoaethoxy)-2-thienyl/-3-phenyl-1-propanone und ihre saeureadditionssalze und verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ATE93524T1 (de) Mitomycinanaloge, verfahren zu ihrer herstellung und pharmazeutische zubereitungen.
ATE23150T1 (de) Aminoethoxybenzylalkohol-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
EP0246529A3 (en) Long acting pyrrolo (2,3-g) isoquinolin-4-one derivatives

Legal Events

Date Code Title Description
IF Valid on the event date
SP73 Change of data on owner

Owner name: SHIRE BIOCHEM INC.; CA

Effective date: 20060111

SP73 Change of data on owner

Owner name: SHIRE CANADA INC.; CA

Effective date: 20090430